Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S165000, C514S235200, C514S252040, C514S314000, C514S921000
Reexamination Certificate
active
07084157
ABSTRACT:
The present invention relates to novel ophthalmic pharmaceutical compositions comprising an inflammation-treating amount of a 4-aminoquinoline compound, derivative, isomers, or chemical salts, and methods for using these compositions for the treatment of ocular inflammatory conditions by topical administration directly to the eye.
REFERENCES:
patent: 5596002 (1997-01-01), Hofheinz et al.
patent: 5948791 (1999-09-01), Hofheinz et al.
Windholz et al., The Merck Index, 1983, Tenth Edition, pp. 304-305, abstract No. 2136; and p. 123, absract No. 863.
Avunduk, AM, et al., Mechanisms and Comparison of Anti-allergic efficacy of Topical Lodoxamide and Cromolyn Sodium Treatment in Vernal Keratoconjunctivitis (2000), Ophthalmology, vol. 107, No. 7, pp. 1333-1337.
Cordes, OD, et al., Plaquenil Toxicity in a Young Patient: Yes or No? (2002), The Southern Journal of Optometry, www.optcom.com/sjo/cordes.htm, pp. 1-6.
De Campos, AM, et al., Chitosan Nanoparticles: A New Vehicle for the Improvement of the Delivery of Drugs to th Ocular Surface. Application to Cyclosporin A (2001), Int. J Pharm, vol. 224, No. 1-2, pp. 159-168.
Dellaert, MMMJ, et al, Influence of Topical Human Epidermal Growth Factor on Postkeratoplasty Re-Epitheliali (May 1997), Br. J. Ophthalmol., vol. 81, pp. 391-395.
Gonzalez Alonso-Alegre, EM, et al., Comparison of Cyclosporin A and Dexamethasone in the Treatment of Canine Nictitans Plasmacytic Conjunctivitis (Jun. 19, 1999) The Veterinary Record, vol. 144, No. 25, pp. 696-701.
Grant, WM, vol. I, Toxicology of the Eye, 2d Ed., pp. 272-273.
Guidera, AC, et al., Keratitis, Ulceration, and Perforation Associated with Topical Nonsteroidal Anti-Inflammatory Drugs (May 2001), Ophthalmology, vol. 108, No. 5, pp. 936-944.
Hillenkamp, J, et al., The Effects of Cidofovir 1% with and without Cyclosporin A 1% as a Topical Treatment of Acute Adenoviral Keratoconjunctivitis, a Controlled Clinical Pilot Study (May 2002), Ophthalmology, vol. 109, No. 5, pp. 845-850.
Kulkarni, P, Review: Uveitis and Immunosuppressive Drugs (2001), Journal of Ocular Pharmacology and Therapeutics, vol. 17, No. 2, pp. 181-187.
Jones, Ocular Toxicity and Hydroxychloroquine; Guidelines for Screening (1999), British Journal of Dermatology, vol. 140, No. 1, pp. 3-7.
Olsen, EG, et al., The Effect of Steroids on the Healing of the Corneal Endothelium, an In Vivo and In Vitro Study in Rabbits (1984), ACTA Ophthalmologica, vol. 62, No. 6, pp. 893-899.
Rynes, RI, Antimalarial Drugs in the Treatment of Rheumatological Diseases (1997), British Journal of Rheumatology, vol. 36, No. 7, pp. 799-805.
Van Der Bijl, P, Effects of Three Penetration Enhancers on Transcorneal Permeation of Cyclosporine (2001), Cornea, No. 20, vol. 5, pp. 505-508.
Lord Nancy
Weddington Kevin E.
LandOfFree
Ophthalmic pharmaceutical compositions and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic pharmaceutical compositions and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic pharmaceutical compositions and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3663418